We have recently demonstrated that simple ratios of the expression levels of selected genes in tumor samples can be used to distinguish among types of thoracic malignancies. We examined whether this technique could predict treatment-related outcome for patients with mesothelioma. Methods: We used gene expression profiling data previously collected from 17 mesothelioma patients with different overall survival times to define two outcome-related groups of patients and to train an expression ratio-based outcome predictor model. A Student's t test was used to identify genes among the two outcome groups that had statistically significant, inversely correlated expression levels; those genes were used to form prognostic expression ratios. We used a combination of several highly accurate expression ratios and cross-validation techniques to assess the internal consistency of this predictor model, quantitative reverse transcription-polymerase chain reaction of tumor RNA to confirm the microarray data, and Kaplan-Meier survival analysis to validate the model among an independent set of 29 mesothelioma tumors. All statistical tests were two-sided. 
Malignant pleural mesothelioma is an asbestos-related, lethal neoplastic disease of the pleura (median survival ‫ס‬ 4-12 months) that can be subdivided into three major histologic subtypes: epithelial, mixed, and sarcomatoid (1) (2) (3) (4) . Compared with patients having the non-epithelial subtypes, patients with the epithelial subtype show a survival benefit from a variety of treatment strategies, including aggressive multimodality therapy (5) (6) (7) . Currently, patients who present to our unit with unilateral mesothelioma without extrapleural invasion undergo complete surgical resection (i.e., extrapleural pneumonectomy) followed by chemoradiation. The 5-year survival for those patients who have Brigham stage I tumors (5) with an epithelial histology is 40%. However, there are no predictive factors, prognostic molecular markers, or genetic abnormalities other than histologic subtype to preoperatively identify these (or other) long-term survivors of pleural mesothelioma. In addition, established methods to predict outcome in mesothelioma that are based on histologic appearance of the tumors are somewhat subjective, prone to human error, and ineffective for small patient cohorts or, in extreme cases, for individual patients (3, 8, 9) .
Gene expression profiling using oligonucleotide microarrays holds promise for improving strategies for tumor classification as well as for predicting response to therapy and survival among cancer patients (10) (11) (12) (13) (14) (15) (16) . Nevertheless, no clear consensus exists regarding which computational tools are optimal for the analysis of large gene expression profiling datasets, particularly when they are used to predict outcome. As a result, microarray-based research has not yet had a substantial impact on the clinical treatment of disease. Recently, we have shown that simple ratios of gene expression levels, using as few as four to six genes, are highly accurate in the diagnosis of cancer, and we hypothesized that this technique would be equally useful in additional clinical applications (17) . To explore this possibility further, we examined whether gene expression profiling data (17) obtained from mesothelioma samples from patients with widely divergent survival times could be used to create an expression ratio-based test capable of predicting outcome among patients diagnosed with mesothelioma in a manner that is independent of the histologic subtype of the tumor.
METHODS

Mesothelioma Tumor Samples
Discarded mesothelioma surgical specimens (n ‫ס‬ 60) were freshly collected from patients who underwent extrapleural pneumonectomy for mesothelioma without preoperative treatment at Brigham and Women's Hospital (Boston, MA) between 1993 and 1999; all specimens were flash frozen (6) . These 60 specimens were chosen from among the 150 available specimens because they contained greater than 50% tumor cell nuclei. The specimens were linked to clinical and outcome data and were provided without patient identifying information. Thirtyone of the specimens were previously profiled using microarrays (17); 17 of those samples were used to train an outcome predictor model (i.e., the training set) and were selected on the basis of linked clinical data in order to construct a sample cohort with a wide range of survival times. The remaining 29 samples (i.e., the test set) were used only for quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis to validate the model (i.e., they had not been previously used in any other analysis). Studies using human tissues were approved by and conducted in accordance with the policies of the Institutional Review Board at Brigham and Women's Hospital.
Real-Time Quantitative RT-PCR
Real-time quantitative RT-PCR was performed using an SYBR-Green fluorometric-based detection system and equipment and reagents purchased from Applied Biosystems (Foster City, CA), according to protocols provided by the manufacturer as previously described (18) . Total RNA (2 g) was isolated from each of the 29 tumors in the test set with the use of TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA), reversetranscribed into complementary DNA (cDNA) with the use of Taq-Man Reverse Transcription reagents (Applied Biosystems), and quantified using all controls recommended by the manufacturer. Primer sequences (synthesized by Invitrogen Life Technologies) used for RT-PCR were as follows (forward and reverse, respectively): L6 (5Ј-TTCCATTCCACAATGTGCTT-3Ј and 5Ј-GGCCAGTGGAACTACACCTT-3Ј), KIAA0977 (5Ј-AACCGAAGCCTAACCTGAGA-3Ј and 5Ј-GTCATTTTGGGA GCAGGTTT-3Ј), GDIA1 (5Ј-AGAAGCAGTCGTTTGTGCTG-3Ј and 5Ј-TGTACTTCATGCCGGACACT-3Ј), and CTHBP (5Ј-ATCTGAAGTTTGGGGTCGAG-3Ј and 5Ј-TCTCTCCCAG GACCTTCCTA-3Ј). PCR amplification of cDNA was performed using an Applied Biosystems 5700 Sequence Detector and default thermal cycling parameters, as previously described (18) . No-template (i.e., negative) controls that contained water instead of template were run in multiple wells on every reaction plate. An automatically calculated melting point dissociation curve generated after every assay was examined to ensure the presence of a single PCR species and the lack of primer-dimer formation in each well. The comparative CT equation (Applied Biosystems) describes the exponential nature of PCR-based amplification and was used, with minor modifications, to obtain quantitative values for gene expression ratios in all samples. The "CT" term stands for the fractional PCR cycle at which the quantity of the amplified product reaches a predetermined threshold. The comparative CT equation states that the expression level of a gene in a given sample, normalized within the sample to an endogenous reference gene and relative to the expression level of the same gene in another sample (i. ] . Calculation of an expression ratio using data from two rationally selected genes in any single sample obviates the need for a calibrator sample and a reference gene for standardization when using different amounts of starting template. Therefore, to form expression ratios of two genes in a single sample, we simply presented the expression level of one gene relative to the expression level of the other gene. In this case, the ⌬⌬C T value in the comparative CT equation was expressed as [CT (gene 1) -CT (gene 2) ].
Data and Statistical Analysis
Expression profiling raw data and supplemental information are available at our Web site, http://www.chestsurg.org, under "Publications." To create an expression ratio-based outcome predictor model in mesothelioma, we used previously collected microarray data (17) to identify genes whose expression levels could be used to discriminate among tumors that came from patients with considerably different survival times. First, we ranked all 31 tumors according to patient survival (irrespective of the histologic subtype of the tumor) and determined the survival times corresponding to the 25 th and 75 th percentile of the cohort (6 months and 17 months, respectively). Then, using these times as a cutoff, we compared gene expression patterns between two groups of mesothelioma samples (i.e., the training set, n ‫ס‬ 17): those that were obtained from patients who had survived for at least 17 months (i.e., good outcome, n ‫ס‬ 8) and those that were obtained from patients who had survived for 6 months or less (i.e., poor outcome, n ‫ס‬ 9). The most accurate expression ratio-based predictor model developed in the training set was subsequently tested in an independent cohort of samples (i.e. the test set, n ‫ס‬ 29). A two-sided Student's (parametric) t test was used for pairwise comparisons of average gene expression levels among multiple groups, and the significance analysis of microarrays (SAM) algorithm (19) was used to estimate the false-discovery rate. To find discriminating genes, we searched all of the genes represented on the Affymetrix U95A 12 000-gene microarray (17) to identify those whose average expression levels differed statistically significantly and by at least twofold between good-outcome and poor-outcome training set tumors. To minimize the effects of background noise, we further refined this list of distinguishing genes by requiring that the mean expression levels (i.e., Affymetrix "average difference" values) be greater than 500 in at least one of the two sample sets, similar to filtering criteria used in previous studies (17) . Kaplan-Meier curves were used to estimate patient survival (defined as the time, in months, from surgery until death) among each group of mesothelioma patients. The log-rank test was used to statistically assess differences among multiple survival curves. A Cox proportional hazards regression model was used for multivariate analysis to identify coefficients that best described the effect of a given variable on censored survival data. (The data conformed to Cox proportional hazards assumptions.) We used the Efron method [described in (20) ] to handle observations with identical survival times. Individual P values reported for multivariate analysis were calculated by considering the Wald statistics of the individual parameters in the combined model. Hazard ratios (HRs) and 95% confidence intervals (CIs) are expressed as the exponentiated coefficient values and are interpretable as multiplicative effects on the hazard. The likelihood ratio test, the Wald test, and the score (i.e., log-rank) test were used to test the null hypothesis that all of the coefficients are zero. The "leave-one-out" method of cross-validation (16) was used to assess internal consistency of the predictor model. Classification accuracy in the test set was determined by using Fisher's exact test (i.e., a 2 × 2 contingency table). All differences were considered statistically significant if P was less than .05. Data from three highly accurate gene expression ratios were combined by calculating the geometric mean, (R 1 R 2 R 3 )
1/3 , where R n represents a single ratio value. This approach is the mathematical equivalent of taking the average of [log 2 (R 1 ), log 2 (R 2 ), log 2 (R 3 )], which gives equal weight to fold-changes in ratios that are of identical magnitude but are in opposite directions. All calculations and statistical comparisons were generated with the use of S-PLUS software (20) . All statistical tests were two-sided.
RESULTS
Identification of Prognostic Molecular Markers in Mesothelioma Tumor Samples
We previously analyzed gene expression levels among a representative cohort of 31 mesothelioma tumors that were obtained from patients at pneumonectomy (17) . In that study, we used differences in global gene expression patterns between the 31 mesothelioma samples and a large number of lung adenocarcinoma samples to develop a ratio-based predictor model to distinguish between these two types of neoplasms. In the current study, we used these data to define molecular markers in mesothelioma that are associated with tumors from patients with widely divergent survival times. The estimated median survival of patients from whom those tumors were obtained (11 months; Fig. 1, A) and the histologic distribution of the tumors were similar to what we have observed among the mesothelioma patients in our practice (6) . The histologic subtype of the tumor was not associated with patient survival (P ‫ס‬ .129, log-rank test; Fig. 1, B) , even though the estimated median survival of patients who had tumors of the epithelial subtype (17 months) was longer than that of patients who had tumors of the nonepithelial subtypes (8.5 months) .
Clinical data for all tumor samples are presented in Table 1 . We identified a total of 46 putative prognostic genes in the analysis of the training set of samples, with an estimated falsediscovery rate of 10%-20%. Table 2 lists, for each outcome group of tumors in the training set, the 10 overexpressed genes that had the lowest P values.
Using Gene Expression Ratios to Predict Outcome
We chose the four genes that were the most statistically significantly overexpressed in each outcome group of tumors (Table 2 ) to examine whether their expression ratios could accurately classify the 17 samples used to train the model with respect to group membership. We calculated a total of 16 possible expression ratios per sample by dividing the expression value of each of the four genes (i.e., those encoding seleniumbinding protein [SBP] , KIAA0977 protein, an expressed sequence tag [EST] similar to the L6 tumor antigen, and leukocyte antigen-related protein [LAR] ) that were expressed at relatively higher levels in good-outcome samples than in poor-outcome samples by the expression value of each of the four genes (i.e., those encoding cytosolic thyroid hormone-binding protein [CTHBP] , calgizzarin, insulin-like growth factor-binding protein-3 [IGFBP-3], and guanosine diphosphate-dissociation inhibitor 1 [GDIA1]) that were expressed at relatively higher levels in poor-outcome samples than in good-outcome samples. Samples with ratio values of greater than 1 were predicted to be good outcome and those with ratio values of less than 1 were predicted to be poor outcome. The individual gene pair ratios that predicted the group membership of the training set samples with the highest accuracy were chosen for further study. Five such ratios (i.e., KIAA0977 protein/IGFBP-3, KIAA0977 protein/GDIA1, L6-related EST/CTHBP, L6-related EST/GDIA1, and LAR/GDIA1) each independently classified 15 (88%) of the 17 samples used to train the model. To incorporate the predictive accuracy of multiple ratios, we calculated the geometric mean (see "Methods" section) for all possible three-ratio combinations (formed using these five ratios) and found that we could classify the training samples with an accuracy that met or exceeded that of any of the single gene-pair ratios (average accuracy ‫ס‬ 94%, range ‫ס‬ 88%-100%). For further analysis, we chose one of the two three-ratio combinations that correctly classified 100% (17/ 17) of the training samples. A total of four genes (those encoding KIAA0977 protein, GDIA1, the L6-related EST, and CTHBP) were used in the following combinations in this three-ratio test: KIAA0977/GDIA1, L6-related EST/CTHBP, and L6-related EST/GDIA1.
Verification of Microarray Data
We used quantitative RT-PCR to determine the relative expression levels of all four prognostic genes (L6, GDIA1, CTHBP, and that encoding the KIAA0977 protein) among three randomly chosen samples from each outcome group in the training set: samples 74, 33, and 68 from the good-outcome group and samples 89, 229, and 67 from the poor-outcome group. We then used the values obtained from RT-PCR quantitation to calculate the three individual expression ratios previously used to predict outcome (i.e., KIAA0977/GDIA1, L6/CTHBP, and L6/GDIA1) for those six samples. Finally, we calculated the geometric mean of these three ratios and compared the magnitude and direction (i.e., >1 or <1) of that value for each of the six samples to that obtained previously by using microarray analysis. We found that outcome group classifications using the threeratio geometric means calculated with data obtained from both types of analyses were in perfect agreement for all six samples (Fig. 1, C) .
Validation of the Model
We used a "leave-one-out" cross-validation technique (16) to assess the internal variation of the three-ratio predictor model. This technique reduces the potential for over-fitting of the model due to an information leak because the sample that is left out of each distinct training set is not involved in the selection of predictor genes (16) . We analyzed 17 different training sets by withholding one of the 17 samples to construct a new expression ratio-based classifier exactly as described above and then predicting the class (either good or poor outcome) of the withheld sample. For each training set, we first identified predictor genes using the original filtering criteria. As before, the four genes that were the most statistically significantly overexpressed in each outcome group (eight genes total) were used to calculate a total of 16 possible expression ratios whose classification accuracies were assessed in the new training set. We then used the geometric mean value for the three most accurate ratios in the new training set to classify the remaining sample. This process was repeated sequentially for all 17 samples. We found that 15 (88%) of the 17 samples were correctly identified by this analysis. In all 17 training sets, two of the four genes used in the original model M  mixed  2  53  3  169  46  M  ept  2  7  3  74  40  F  ept  1  51  2  146  67  M  ept  2  7  3  90  48  M  ept  2  28  2  219  39  M  ept  2  6  1  2  44  F  ept  2  26  2  104  40  M  ept  2  5  3  68  61  M  ept  2  21  3  110  64  M  ept  2  5  3  33  60  F  ept  2  20  3  112  31  M  ept  2  55  3  109  62  M  ept  2  19  3  165  51  M  ept  2  27  2  76  67  M  ept  1  17  3  5  51  M  ept  2  8  3  130  55  M  mixed  2  6  3  148  51  M  ept  2  17  3  166  66  M  sarc  2  6  3  96  40  M  ept  2 (i.e., those encoding KIAA0977 protein and the L6-related EST) were present among the final list of eight genes. The final threeratio test used to classify each left-out sample included both of these genes in one training set, one of these genes in 12 training sets, and neither of these genes in four training sets.
Verification of Expression Level Ratios as Outcome Predictors
Finally, we tested the ability of expression ratios to predict patient outcome among a new cohort of mesothelioma tumor samples that had not been subjected to microarray analysis (n ‫ס‬ 29, the test set; Table 1 ). The estimated median survival of patients from whom those tumors were obtained (12 months; Fig. 2, A) and the histologic distribution of the test set tumors were similar to what we observe among mesothelioma patients in our practice (6) . The histologic subtype of the tumors in the new cohort of samples was not associated with patient survival (P ‫ס‬ .345, log-rank test; Fig. 2, B) . We used quantitative RT-PCR to determine the relative expression levels of the four predictor genes among the test set samples and calculated the geometric mean of three prognostic expression ratios: KIAA0977/GDIA1, L6/CTHBP, and L6/GDIA1. Samples with geometric means of greater than 1 and less than 1 were assigned to good-outcome and poor-outcome groups, respectively; 11 samples were assigned to the good-outcome group, and 18 samples were assigned to the poor-outcome group. The number of test set samples "correctly" classified was estimated by using the median survival (12 months) of the entire cohort as a cutoff to form two groups: the relatively good-outcome group (>12-month survival) and the relatively poor-outcome group (ഛ12-month survival). When we considered only the 17 samples that came from patients who had died from malignant pleural mesothelioma (status 3; Table 1 ), we found that the exact same number of test set samples were classified correctly in this analysis (88%, 15/ 17; P ‫ס‬ .0099, Fisher's exact test) as were classified correctly in our analysis of the training set samples. To include all samples in an assessment of the model, we performed Kaplan-Meier survival analysis using expression ratio predictions made for the test set of samples. The estimated median survival for the goodoutcome group (36 months) was more than fivefold higher than that for the poor-outcome group (7 months). In addition, we found that the three-ratio geometric mean model statistically significantly predicted outcome in the test set of samples (P ‫ס‬ .0035, log-rank test; Fig. 2, C) . Because it has been demonstrated in very large sample cohorts that patients whose tumors have epithelial histologies generally enjoy statistically significantly longer disease-free survival than patients whose tumors have non-epithelial histologies (21), we used multivariate analysis to examine whether the results we obtained using expression ratios were independent of the histologic subtype of the tumor. By fitting a Cox proportional hazards regression model, we found that the three-ratio geometric mean value statistically significantly predicted outcome (HR ‫ס‬ 4.6, 95% CI ‫ס‬ 1.5 to 14.8; P ‫ס‬ .0094), whereas the histologic subtype of the tumor did not (HR ‫ס‬ 1.2, 95% CI ‫ס‬ 0.45 to 3.1; P ‫ס‬ .75). Furthermore, the results of a likelihood ratio test (P ‫ס‬ .011), a *EST ‫ס‬ expressed sequence tag; GDP ‫ס‬ guanosine diphosphate; LIM ‫ס‬ acronym for Lin-11, Isl-1, and Mec-3. †Average expression level in good outcome samples/average expression level in poor outcome samples. ‡P values were obtained using a two-tailed Student's t test to identify genes whose average expression levels were statistically significantly different between groups of tumor samples from patients with good and poor outcome, respectively, as detailed in the "Methods" section.
§IGFBP-3 is listed twice in the lower portion of the table because this gene is represented by multiple Affymetrix probe sets. Each microarray probe set is complementary to a unique DNA sequence and, because the probe sets are composed of relatively short sequences, a certain number of them are capable of specific hybridization to different regions of the same gene. When this occurs, it provides a direct, internal measure of confidence in relevant gene expression levels. In addition to the duplication of IGFBP-3, note that both the L6 gene and an EST with high sequence homology to L6 are represented in the table.
Wald test (P ‫ס‬ .025), and a score (i.e., log-rank) test (P ‫ס‬ .013) were all in close agreement, leading to the rejection of the null hypothesis, i.e., that at least one of the regression coefficients is not zero. These results demonstrate that expression ratios can predict outcome in mesothelioma independently of the histologic subtype of the tumor in an independent set of samples, indicating that the gene expression ratio method is a better prognostic tool than histology.
DISCUSSION
Current methods of prognosis in mesothelioma include determining tumor stage and histology at the time of surgery. However, these techniques are not completely reliable, and accurate staging usually requires extensive surgery (3, 8, 9) . Recently, we discovered that simple ratios of gene expression levels can be used to accurately diagnose cancer (17) while successfully avoiding many of the shortcomings that preclude the use of other analytical microarray techniques in wider clinical applications (10, 22) . In this study, we describe a technique that used expression data from four genes to independently predict outcome in mesothelioma patients who had undergone extrapleural pneumonectomy followed by standard chemoradiation therapy. Although this analysis used expression data from only four genes, the expression ratio technique can easily incorporate data from larger numbers of genes when required to achieve acceptable levels of accuracy. To our knowledge, ours is the first study to use gene expression profiling techniques to identify treatmentrelated prognostic markers for a human cancer that can be used to develop an outcome predictor model and to validate the model in an independent cohort by using a simple data acquisition platform such as RT-PCR. Other investigators have tested outcome predictor models in independent samples (16, 23, 24) , but those studies continue to be restricted in their clinical applicability because they rely on data gathered from relatively large numbers of genes, costly data acquisition platforms (i.e., microarrays), and sophisticated algorithms and/or software and are unable to analyze a sample independently and without reference to other samples.
The prognostic tool described herein could dramatically influence the current clinical treatment of mesothelioma by allowing the identification of those patients who are unlikely to respond to conventional treatment modalities, thus sparing them from radical surgery. It is currently our practice to obtain a tissue diagnosis before recommending therapy for patients with mesothelioma, but the absence of suitable prognostic molecular markers makes it difficult to assign optimal treatments or to investigate new modalities solely on the basis of tumor histology. The The estimated median survival for this cohort was 12 months. B) Overall survival of patients whose tumors composed the test set according to the histologic subtype of the tumor. The median survival for patients with epithelial subtype tumors (solid line) was 17 months, and the median survival for patients with non-epithelial subtype tumors (dashed line) was 12 months. C) Overall survival in the test set of samples for good-outcome (solid line; median survival ‫ס‬ 36 months) and poor-outcome (dashed line; median survival ‫ס‬ 7 months) groups as defined by the four-gene expression ratio model that used only reverse transcription-polymerase chain reaction for data acquisition. N and S indicate the number of patients at risk and the Kaplan-Meier estimate of overall survival, respectively, at the indicated time points. CI ‫ס‬ 95% confidence interval for the Kaplan-Meier survival estimate.
results of this work, if confirmed prospectively in a larger patient population, should prove helpful in the development of meaningful clinical trials for patients with mesothelioma. We hypothesize that patients whose tumors are analyzed using gene expression ratios and are predicted to have relatively poor outcomes are excellent candidates for neo-adjuvant chemotherapy protocols because they are unlikely to benefit from surgery followed by chemotherapy and radiation (i.e., current standard treatment for mesothelioma), whereas patients predicted to have relatively good outcomes are more likely to enjoy longterm survival after conventional surgery and adjuvant chemoradiation.
The use of gene expression ratios to predict outcome in cancer patients overcomes several major obstacles that hinder the clinical use of microarray data. Unlike other widely accepted supervised learning techniques with similar predictive accuracy (10, 16, (22) (23) (24) , the expression ratio method generates a simple numeric measure that can be used to predict clinical outcome by using a single biopsy specimen. The gene expression ratio method, by virtue of the fact that it generates a ratio, 1) negates the need for a third reference gene when determining expression levels, 2) is independent of the platform used for data acquisition, 3) requires only small quantities of RNA (as little as 10 pg when using RT-PCR), 4) does not explicitly require the coupling of transcription to translation for chosen genes or rely on subjective measures of expression (as is the case for immunohistochemical analysis), 5) permits analysis of individual samples without reference to additional training samples whose data were acquired on the same platform, and 6) can use any reliable method to quantify expression levels, including quantitative RT-PCR, cDNA and oligonucleotide microarrays, serial analysis of gene expression and, perhaps, enzyme-linked immunosorbent assays for encoded proteins. For these reasons, the gene expression ratio method is more likely to find immediate use in clinical settings because it confers several advantages that are lacking in other equally accurate techniques, such as standard linear discriminant analysis. In fact, the expression ratio technique can be thought of as a special case of linear discriminant analysis wherein the threshold, while perhaps not optimal, remains constant across experiments but still results in highly accurate classification.
We believe that attempts to bridge the gap between expression profiling studies in cancer and meaningful clinical applications should follow the general spirit of Occam's razor, a principle according to which "among a set of otherwise equal models, choose the simplest." Although other microarray-based predictor models in cancer may use relatively small numbers of genes to accurately predict outcome (16, 21, 24, 25) , those approaches continue to be limited in their clinical applicability. Furthermore, it has yet to be determined whether those approaches can use relatively low-cost and widely available data acquisition platforms such as RT-PCR and still allow statistically significant survival predictions. In this study we have shown that expression ratios can be useful in predicting prognosis in mesothelioma. In other clinical scenarios, the differences in gene expression patterns between groups to be distinguished may be more subtle, thus necessitating the modification of the filtering criteria used to select potential predictor genes. In addition, a rationally chosen threshold value other than 1 may be indicated when the baseline levels of expression of the predictor genes are very different. Nevertheless, it is likely that the expression ratio technique will find additional uses in the clinical management of other cancers and diseases. For example, using previously published data, we created ratio-based tests that use small numbers of genes that can be used to diagnose localized prostate cancer and predict clinical outcome in breast cancer (Gordon GJ, Loughlin KR, Powell MH, Sugarbaker DJ, Bueno R: unpublished data) and to predict clinical outcome in lung cancer (Gordon GJ, Richards WG, Sugarbaker DJ, Jaklitsch MJ, Bueno R: unpublished data).
